Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Gemcitabine + Itacitinib + Nab-paclitaxel
Indication/Tumor Type Advanced Solid Tumor
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Gemcitabine + Itacitinib + Nab-paclitaxel Phase Ib/II Actionable In a Phase Ib/II trial, Itacitinib (INCB039110) in combination with nab-paclitaxel and gemcitabine demonstrated safety and preliminary efficacy, resulted in an overall response rate of 24% (13/55, all partial responses) in patients with advanced solid tumors (PMID: 30115734; NCT01858883). 30115734
PubMed Id Reference Title Details
(30115734) A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. Full reference...